López RM, Santamaría S, Vargas RI

Idioma: Español
Referencias bibliográficas: 21
Paginas: 80-89
Archivo PDF: 85.31 Kb.

FRAGMENTO

En el año 1875 Horacio C. Wood en su libro Treatise on therapeutics describió la presencia de “Convulsiones faciales limitadas a los orbiculares de los párpados, que cierran completamente los ojos y se acompañan de múltiples gestos bizarros”.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cambur A, et al. Meige’s Síndrome Associated With Neuroleptic Treatment. Am J Psychiatry 1988; 145: 4.

2. Yoshimura R, et al. Effect of clonazepam treatment on antipsychotic drug induced Meige síndrome and changes in plasma levels of GABA, HVA, and MHPG durin treatment. Psychiatry and Clinical Neurociences 2001: 55: 543-6.

3. Mauriello JA, et al. Treatment selections of 239 patients with blepharospasm and Mege síndrome over 11 years. British J Ophtalmol 1996; 80: 1073-6.

4. Hayashi T, et al. Neuroleptic – induced Meige’s syndrome following akathisia: Pharmacologic characteristics. Psychiatry Clin Neurosci 1998: 52(4): 445-8.

5. Lozano D y cols. Bloqueo neuromuscular con alcohol en el blefaroespasmo esencial, síndrome de Meige y espasmo hemifacial. Arch Neurocien (Méx) 2006; 11(2): 85-9.

6. Yardimci N, et al. Levetiracetam in Meige’s syndrome. Acta Neurol Scand 2006: 114: 63-66.

7. Ransmayr G, et al. Pharmacological Study in Meige’s Syndrome with Predominant Blepharospasm. Clinical Neuropharmacology 1998: 11(1): 68-76.

8. Gordon JG. Brueghel syndrome: its distinction from Meige syndrome. Neurology 1996; 46: 1767-9.

9. Del Val LJ, Castro GA. Toxina botulínica: Aplicaciones Terapéuticas. MASSON, S. A.; 2002.

10. Bhidayasiri R, et al. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol 2006; 13(Suppl. 1): 21-9.

11. Eng-King Tan, Jankovic J. Tardiv and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiat 2000; 68: 2.

12. Sankla Ch, Lai EC, Jankovic JJ. Peripherally induced oromandibular dystonia. Neurol Neurosurg Psychiatry 1998; 65; 722-8.

13. Simpson DM, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-basad review) Neurology 2008; 70: 1699-706.

14. Balash Y, Giladi N. Efficacy of Pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004; 11: 361- 70.

15. Moller E, et al. Treatment of perioral dystonia with botulinum toxin in 4 cases of Meige’s syndrome. Oral Surgery Oral Medicine Oral Pathology 2003.

16. Neuenschwander MC, et al. Botulinum toxin in otolaryngology: a review of its actions and opportunities for use. Ear, Nose and Throad Journal 2000; 79: 10.

17. Tintner R, Jankovic J. Botulinum toxin type A in the Mangement of Oromandibular Dystonia and Bruxism. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia, PA: Lippincott Williams and Wilkins; 2002.

18. Hermanowicz N, et al. Treatment of Oromandibular Dystonia with Botulinum Toxin. Laringoscope 1991; 101.

19. Schneider SA, et al. Severe tongue protusion dystonia Clinical sindromes and possible treatment. Neurology 2006; 67: 940-3.

20. Charles PD, et al. Tongue Protusion Dystonia: treatment with Botulinum Toxin. South Med J 1997; 90(5).

21. Yoshimura R, et al. Effect of clonazepam treatment on antipsychotic drug-induced Meige syndrome and changes in plasma levels of GAVA, HVA, and MHPG during treatment. Psichiatry and Clinical Neurosciences 2001: 55: 543-6.